Ladasten plus fabomotizole in a paraquat-induced parkinsonian mouse model
V. E. Marievsky, I. A. Lyubansky, S. V. Shangin, L. F. Zaynullina, V. L. Dorofeev · 2025 · Pharmacokinetics and Pharmacodynamics. 2025;(1):43–52.
Study findings
The combination improved motor-test performance relative to the paraquat-exposed control group, with the largest reported differences in the third week.
- Population and setting
- C57BL/6 mice; four groups including controls, combination treatment and levodopa
- Evidence type
- Animal / experimental
- Source language
- Russian
- Title source
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
Study limitations
- Animal toxin model, not a Parkinson disease treatment trial in people.
- The abstract does not report separate Ladasten-only and fabomotizole-only arms; it cannot establish synergy or each component’s contribution.
- Combination dose and full methods require the original paper; paraquat induction dose is not the treatment dose.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Abstract-level record
Source access and review scope
Primary journal abstract reproduced by the Russian Central Scientific Medical Library checked.
Recorded source-check date: 2026-10-08. This date does not imply a completed systematic review.
Citation and original source
Original source: V. E. Marievsky, I. A. Lyubansky, S. V. Shangin, L. F. Zaynullina, V. L. Dorofeev. Ladasten plus fabomotizole in a paraquat-induced parkinsonian mouse model Pharmacokinetics and Pharmacodynamics. 2025;(1):43–52. 2025.
Molekul research summary: https://molekul.io/research/refresh-bromantane-fabomotizol-2025. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry